Clinical trials
Recurrent Glioma clinical trials
Below are recruiting recurrent glioma clinical trials, each written for real people, not researchers. We’re tracking 79 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05345002RecruitingPhase 2
ATRA plus PD-1 therapy for IDH-mutant recurrent brain tumors
This trial studies whether adding all-trans retinoic acid (ATRA) to an anti–PD-1 immune therapy can slow recurrent or worsening IDH-mutant glioma. It may help by boosting the immune system’s attack on the tumor.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07017816RecruitingEarly Phase 1
Gene therapy, checkpoint inhibitor, and radiation for children with brain cancer
This trial tests a new combination treatment for children and young adults with brain tumors that have come back or not responded to standard therapy. The treatment includes a gene therapy (SGT-53) that delivers a normal TP53 gene, a checkpoint inhibitor drug that helps the immune system attack the cancer, and focused radiation. The goal is to see if this combination is safe and can shrink tumors.
Washington D.C., District of ColumbiaAges 3–21 - NCT07831369RecruitingPhase 2
Drug combination for recurrent glioma
This trial tests a combination of three drugs—valproic acid, irinotecan, and simvastatin—to see if they can help people whose brain tumor (glioma) has come back despite earlier treatment. The goal is to slow or stop tumor growth.
Fairfax, VirginiaAges 18–98 - NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT04794972RecruitingPhase 1
Testing a targeted antibody for advanced solid tumors
This Phase 1 trial tests a new antibody drug (GNC-039) that targets a specific feature found on some cancer cells. It is for adults with solid tumors that have come back or stopped responding to standard treatment, aiming to see safety and early signs of effectiveness.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03122197RecruitingEarly Phase 1
Letrozole for recurrent high-grade brain tumors
This early-phase study tests letrozole, a hormone-blocking medicine, in adults with recurrent high-grade gliomas. The goal is to see if it can help control the tumor and is safe enough to study further.
Cincinnati, OhioAges 18 years+ - NCT06330337RecruitingPhase 3
Electroacupuncture plus paclitaxel for recurrent high-grade glioma
This trial tests whether adding electroacupuncture (a type of acupuncture with mild electric pulses) to the chemotherapy drug paclitaxel can help people with recurrent high-grade glioma. The goal is to see if the combination works better than paclitaxel alone.
ZhejiangAges 18–70 - NCT06818331RecruitingPhase 2
Electroacupuncture study for recurring brain cancer
This trial tests if a special type of electroacupuncture can help chemotherapy (paclitaxel) reach the brain more effectively in patients whose high-grade glioma has come back after surgery. The goal is to see if this combination can slow tumor growth.
China, Hangzhou City, Zhejiang ProvinceAges 18–70 - NCT04185038RecruitingPhase 1
CAR T therapy through a catheter for pediatric brain tumors
This Phase 1 trial tests a personalized immune-cell treatment (CAR T) delivered directly in the brain-area space using a catheter. It may help children and young adults with hard-to-treat (recurrent or refractory) diffuse midline brain tumors like DIPG/DMG when standard options aren’t working.
Seattle, WashingtonAges 1–26 - NCT05588141RecruitingPhase 1/Phase 2
Zotiraciclib for recurrent brain tumors with IDH mutations
This early-phase study tests zotiraciclib in people with recurring diffuse gliomas (brain tumors) that have an IDH1 or IDH2 mutation. It may help slow the tumor or shrink it by targeting a specific change in tumor biology.
Bethesda, MarylandAges 15 years+ - NCT05139056RecruitingPhase 1
Stem cell virus therapy for recurrent brain tumors
This trial tests a new treatment that uses specially modified stem cells (taken from donors) to deliver a virus directly into the tumor during surgery. The goal is to see if it is safe and effective for brain tumors that have come back after standard therapy.
Duarte, CaliforniaAges 18 years+ - NCT06838676RecruitingPhase 2
ACT001 for Newly or Previously Treated Brain Stem Glioma
This trial tests the drug ACT001 in people with a type of brain tumor called DIPG or other related high-grade gliomas. It aims to see if the drug can help control the tumor and improve outcomes.
Aurora, ColoradoAges 1–39 - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT07306299RecruitingPhase 1
MRNA vaccine for recurrent high-grade glioma
This trial tests a new mRNA vaccine for people with a type of brain tumor called high-grade glioma that has come back or progressed. The vaccine is designed to help your immune system recognize and attack the tumor cells.
Hangzhou, ZhejiangAges 16 years+ - NCT07268053RecruitingEarly Phase 1
B7-H3 drug for recurrent brain tumor or brain metastases
This trial tests a drug called GSK5764227 (a B7-H3 targeted antibody-drug conjugate) in people whose glioblastoma has come back after standard treatment, or who have brain metastases that need surgery. The goal is to see if the drug can help shrink or control the tumor.
Phoenix, ArizonaAges 18 years+ - NCT06126744RecruitingPhase 1
Study of a virus therapy for recurrent brain cancer
This trial tests a virus-based treatment called MVR-C5252 for people whose high-grade glioma or glioblastoma has come back after standard therapy. The virus is injected directly into the tumor to try to kill cancer cells and boost the immune system. The goal is to see if it is safe and if it can shrink the tumor.
New York, New YorkAges 18 years+ - NCT03643549RecruitingPhase 1/Phase 2
Combination treatment for recurring brain cancer
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
BergenAges 18 years+ - NCT05609994RecruitingPhase 1
Vorasidenib plus a peptide vaccine for recurrent low-grade glioma
This Phase 1 study tests vorasidenib combined with a personalized tumor-targeting peptide vaccine in adults with a specific type of recurrent brain tumor. It aims to see how safe the combination is and whether it can help slow the tumor’s growth.
Durham, North CarolinaAges 18 years+ - NCT06482905RecruitingPhase 1
CAR-T cell therapy for recurrent grade 4 brain tumors
This trial tests a new treatment called TX103 CAR-T cells for people with a grade 4 glioma (like glioblastoma) that has come back or gotten worse after standard treatment. The therapy uses your own immune cells that are specially trained to attack a marker called B7-H3 found on tumor cells.
Phoenix, ArizonaAges 18–75 - NCT06072586RecruitingEarly Phase 1
Study of BDTX-1535 for brain tumors with EGFR changes
This trial tests a new drug, BDTX-1535, for people with a type of brain tumor called high-grade glioma that has a specific change in the EGFR gene. The study looks at how the drug works in the body and how safe it is for both newly diagnosed and recurrent tumors.
Chandler, ArizonaAges 18 years+ - NCT05917145RecruitingPhase 1
Drug WSD0628 plus radiation for recurrent brain tumor
This Phase 1 trial tests a new cancer drug (WSD0628) given with radiation for people whose high-grade glioma has returned after prior treatment. The goal is to find a safe dose and see how well the treatment works in this situation.
Rochester, MinnesotaAges 18 years+ - NCT06496971RecruitingPhase 3
Testing focused ultrasound plus Avastin for recurrent glioblastoma
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
TaipeiAges 18–80 - NCT06444412RecruitingPhase 2
Testing a new PET scan to detect brain tumor recurrence
This trial tests a special imaging scan called Ga-68 PSMA-11 PET/CT to see if it can better detect when a glioma brain tumor has come back or progressed. It is for people who have already had standard treatment and are planning surgery for a suspected recurrence.
Rochester, MinnesotaAges 18 years+ - NCT07710690RecruitingPhase 1
Study of NRG-103 injection for recurrent high-grade glioma
This trial tests a new injection called NRG-103 for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard treatments. The goal is to see if it's safe and if it might help shrink the tumor.
ShanghaiAges 18 years+
Hear when a new Recurrent Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent glioma?
- Yes. Clin2 currently lists 79 recruiting recurrent glioma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent glioma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent glioma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.